GO
Loading...

Glaxo to Buy Biotech Domantis for $450 Million

GlaxoSmithKline agreed to buy privately owned biotech company Domantis, a specialist in developing a new generation of antibody drugs, for 230 million pounds ($452.8 million).

Europe's biggest drugmaker said Domantis would become part of its biopharmaceuticals drug discovery unit while continuing to operate from laboratories in Cambridge, England.

The deal is the latest in a string of recent biotech acquisitions by large pharmaceutical companies eager to boost their pipelines of new medicines.

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    › Learn More

Don't Miss

U.S. Video

  • A Bank of America branch is shown in New York's Times Square.

    CNBC's Kate Kelly reports Bank of America has reached a landmark $17 billion settlement with the Justice Department over mortgage backed securities.

  • Discussing the Fed's interest rate plan and the continued market rally, with Keith Fitz-Gerald, Money Map Press; Jack Bouroudjian, Index Financial Partners; Abigail Doolittle, Peak Theories; and CNBC's Rick Santelli and Steve Liesman.

  • Rick Horrow, Horrow Sports Ventures president, shares his opinions on safety in sports, as well as enhancing the fan experience with technology to get fans "off the couch."